Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Standard Biotools (LAB) Finished Goods (2016 - 2025)

Standard Biotools (LAB) has disclosed Finished Goods for 15 consecutive years, with $11.1 million as the latest value for Q4 2025.

  • Quarterly Finished Goods rose 52.85% to $11.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $11.1 million through Dec 2025, up 52.85% year-over-year, with the annual reading at $11.1 million for FY2025, 52.85% up from the prior year.
  • Finished Goods for Q4 2025 was $11.1 million at Standard Biotools, down from $12.7 million in the prior quarter.
  • The five-year high for Finished Goods was $15.2 million in Q4 2022, with the low at $7.3 million in Q4 2023.
  • Average Finished Goods over 5 years is $11.0 million, with a median of $11.0 million recorded in 2021.
  • The sharpest move saw Finished Goods soared 60.21% in 2021, then tumbled 52.38% in 2023.
  • Over 5 years, Finished Goods stood at $10.6 million in 2021, then surged by 43.64% to $15.2 million in 2022, then crashed by 52.38% to $7.3 million in 2023, then changed by 0.0% to $7.3 million in 2024, then soared by 52.85% to $11.1 million in 2025.
  • According to Business Quant data, Finished Goods over the past three periods came in at $11.1 million, $12.7 million, and $13.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.